Novaccess Global Inc - XSNX STOCK NEWS

NovAccess Global Inc. (OTCQB:XSNX) has announced a series of fireside chat interviews scheduled for the next four months. These sessions aim to discuss significant topics related to the company and the biomedical field, with interviews scheduled on October 6, November 3, December 1, and January 5, 2023. The sessions, accessible online, will feature insights from board members and the CEO. NovAccess is focused on developing immunotherapies for brain tumor patients, particularly targeting glioblastoma, and aims to enhance patient immune responses through its innovative cancer vaccine therapy.

NovAccess Global Inc. (OTCQB:XSNX) announced the effectiveness of its Form S-1 registration statement as of September 16, 2022, enabling the distribution of 7.5 million shares to Innovest Global, Inc. shareholders. This move is part of a strategic initiative to enhance liquidity and expand the company’s shareholder base, promoting its novel immunotherapy platform for brain tumor therapy. The company aims for further uplift to a national exchange, such as Nasdaq or NYSE American, following its recent upgrade to the OTCQB market.

NovAccess Global Inc. (OTC PINK:XSNX) has filed an application with the U.S. FDA for Orphan Drug Designation for its vaccine immunotherapy TLR-AD1, aimed at treating aggressive brain cancers like glioblastoma multiforme (GBM). GBM affects around 250,000 people globally each year, with 10,000 deaths in the U.S. alone. The global GBM treatment market was over $2 billion in 2020, expected to grow over 8% annually. If granted, the designation would provide numerous benefits, accelerating development and enhancing NovAccess's intellectual property portfolio.

NovAccess Global (OTC PINK:XSNX) announced that CEO Dr. Dwain Irvin was featured on MoneyTV, an internationally-syndicated business program reaching over 180 million households. During the interview, Dr. Irvin discussed the company's novel immunotherapy for brain tumors, its upcoming orphan drug filing, and a planned Phase I IND application with the FDA, potentially leading to a Phase IIa application. The company's patented technology aims to enhance the immune response in glioblastoma patients, which poses significant survival challenges.

NovAccess Global (OTC PINK:XSNX) will have its CEO, Dr. Dwain Irvin, at the LD Micro Invitational XII Conference from June 7-9, 2022, at the Four Seasons Hotel in Westlake Village, CA. The company will present on June 7 at 4:00 PM PT and will host investor meetings throughout the day. Presentation materials will be available on the company’s website. NovAccess is focused on developing innovative cancer therapies, particularly a cancer vaccine therapy aimed at improving treatment for brain tumor patients. This includes a recent patent for using vaccination therapy in cancer treatment.

NovAccess Global (OTC PINK:XSNX) has completed key transactions that drastically reduce potential common stock dilution by 97.6% and expand its shareholder base. These include the redemption of 24,400 of 25,000 preferred shares and a stock distribution agreement with Innovest Global to distribute 7.5 million shares, expected to double NovAccess's shareholders. CEO Dr. Dwain K. Irvin joins the board alongside independent member John A. Cassarini. These steps improve capital structure and aim for uplisting to a national exchange while advancing cancer diagnostics and therapeutics.

NovAccess Global (OTC PINK:XSNX) announced that CEO Dr. Dwain Irvin will attend the BIO CEO and Investor Conference in New York from February 14-17, 2022. The conference aims to connect industry executives with Wall Street investors. NovAccess is focused on developing novel immunotherapies for brain tumor patients and has received a patent for its cancer vaccine technology. The company plans to uplist on OTCQB, file for orphan drug status, and submit a Phase IIa IND application to the FDA. For additional details, visit novaccessglobal.com.

NovAccess Global (OTC PINK:XSNX) has appointed Neil Laird as the new Chief Financial Officer, following the contributions of former CFO Mike Yukich. Laird brings extensive experience in finance, having previously held CFO roles at Mobileum Inc. and SumTotal Systems. NovAccess is focused on developing innovative cancer diagnostics and therapeutics, including a cancer vaccine therapy targeting glioblastoma multiforme, which has a challenging prognosis. The company aims to enhance patient immune response against tumors, potentially improving outcomes for cancer patients.